Drugs / ATX2417
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02316912 Comparator | Feb 2015 → Apr 2016 | allergic disease | Atopix Therapeutics, Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATX2417 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02316912 ↗ |
| Route | Oral | “First in Man Evaluation of Single and Multiple Doses of Oral ATX2417” NCT02316912 ↗ |